Jade Biosciences (JBIO) Current Assets (2020 - 2026)
Jade Biosciences' (JBIO) quarterly Current Assets came in at $318.5 million in Q1 2026, up 311.66% YoY from $77.4 million in Q1 2025, and down 8.69% on a QoQ basis from $348.8 million in Q4 2025.
Jade Biosciences (JBIO) Current Assets (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Current Assets data on file, last reported at $318.5 million in Q1 2026.
- Quarterly Current Assets rose 311.66% year-over-year to $318.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $318.5 million (up 311.66% YoY) and the FY2025 annual result came in at $348.8 million, up 400.78% from the prior year.
- Current Assets declined to $318.5 million in Q1 2026, from $348.8 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $348.8 million in Q4 2025 to a low of $69.7 million in Q4 2024.
- A 5-year average of $157.3 million and a median of $137.6 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets slumped 43.93% — and 2025, when it soared 400.78%.
- Tracing JBIO's Current Assets over 5 years: stood at $131.5 million in 2022, then retreated by 5.52% to $124.2 million in 2023, then tumbled by 43.93% to $69.7 million in 2024, then soared by 400.78% to $348.8 million in 2025, then dropped by 8.69% to $318.5 million in 2026.
- The last three Current Assets figures came in at $318.5 million (Q1 2026), $348.8 million (Q4 2025), and $201.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | 471.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 471.25 Mn |
| Mar 31, 2026 | 318.52 Mn |
| Dec 31, 2025 | 348.82 Mn |
| Sep 30, 2025 | 201.36 Mn |
| Jun 30, 2025 | 222.98 Mn |
| Mar 31, 2025 | 77.37 Mn |
| Dec 31, 2024 | 69.65 Mn |
| Sep 30, 2024 | 90.61 Mn |
| Jun 30, 2024 | 110.76 Mn |
| Mar 31, 2024 | 103.24 Mn |
| Dec 31, 2023 | 124.23 Mn |
| Sep 30, 2023 | 137.60 Mn |
| Jun 30, 2023 | 152.47 Mn |
| Mar 31, 2023 | 120.57 Mn |
| Dec 31, 2022 | 131.50 Mn |
| Sep 30, 2022 | 145.16 Mn |
| Jun 30, 2022 | 153.45 Mn |
| Mar 31, 2022 | 165.89 Mn |
| Dec 31, 2021 | 174.33 Mn |
| Sep 30, 2021 | 183.10 Mn |